Access Vascular Appoints Jeff Gaus as National Sales Director
BILLERICA, MA – June 19, 2024 – Access Vascular (AVI), a leading innovator in vascular access technology, is pleased to announce the appointment of Jeff Gaus as the National Sales Director. Gaus brings over 20 years of sales and leadership experience, across both large companies and startups, to his new role at AVI. In his role, Gaus will be responsible for driving national sales strategies, expanding market reach, and fostering relationships with key stakeholders and customers.
"We are excited to welcome Jeff to the Access Vascular team," said James Biggins, President and CEO of Access Vascular. "His extensive experience and proven track record in sales leadership will be instrumental in building on our exponential growth and expanding our market presence."
"I am honored to join Access Vascular and lead the national sales efforts," said Jeff Gaus. "This is a pivotal time for the company, and I look forward to working with this talented team to achieve our ambitious growth objectives and deliver much-needed innovative vascular access solutions to our customers."
This announcement coincides with another organizational change and promotion. Rick Biro, who previously held the title of National Sales Director, is now the Senior Director of Business Development and Strategic Partnerships. Rick will be responsible for business development and collaboration with the company's strategic partners. Rick has been instrumental in our triple digit growth over the last 18 months and in this new role will focus on the larger opportunities for continuing to expand and grow the business.
Access Vascular's MIMIX® technology is at the forefront of innovation, offering a unique material designed to minimize complications associated with vascular access devices. Until this year, Access Vascular was in a Limited Market Release (LMR) product launch with a focus on refining the biomaterial technology for superior clinical outcomes by partnering with select high-volume accounts. Now that the technology has been clinically validated with multiple real-world publications and in vitro data, 2024 will be the first full year of widespread commercialization.
The patented MIMIX® material used in AVI’s HydroPICC®, HydroPICC® Dual, and HydroMID® catheters has shown a six-fold decrease in complications compared with standard polyurethane catheter material.[i] Additionally, data was recently presented at the 2024 Infusion Nurses Society conference demonstrating a 99.99% reduction in bacterial adhesion and 97 percent reduction in thrombus accumulation as compared to an anti-microbial polyurethane catheter.[ii]
About Access Vascular
Access Vascular was founded to address the most common and costly complications of intravenous therapy: infection, thrombosis, and phlebitis. Taking a foundationally different approach to thrombus reduction, the company manufactures intravenous catheters from a proprietary hydrophilic material. Engineered to mimic the body’s natural chemistry, Access Vascular catheters are designed to evade the foreign body response and the complications that come with it. Our award-winning, FDA-cleared products are HydroPICC® and HydroMID®. For more information, please visit www.accessvascularinc.com, and follow us on LinkedIn.
References
[i] Bunch J. A retrospective assessment of peripheral midline failures focusing on catheter composition. J InfusNurs. Sept/Oct 2022; 45(5):270-27
[ii] Korycka, E. Presented at INS 2024. Reduction of thrombus accumulation was evaluated using in vitro and models. Pre-clinical in vitro valuations do not necessarily predict clinical performance with respect to thrombus formation.
